


SpinalCyte launches initiative to highlight advances in Fibroblast Technology

17 May 2019 | News

SpinalCyte is the leader in the field of HDF therapy with 52 U.S. and international patents issued and 85+ patents pending focused on the clinical utility of fibroblasts.

image not found or type unknown



SpinalCyte, LLC, a clinical-stage regenerative medicine company focused on regrowth of the spinal disc using Human Dermal Fibroblasts (HDFs) has announced a new comprehensive resource to raise awareness of the potential benefits of fibroblasts and provide a growing knowledge base for this promising regenerative medicine technology.

“Fibroblasts hold significant advantages over mesenchymal stem cells,” said Dr. Thomas Ichim, Chief Scientific Officer of SpinalCyte and author of an analysis comparing the two cell sources published in the *Journal of Translational Medicine*. “As we and other leading researchers continue to advance the science in this field, our website will be the best place to find the latest and most up-to-date information on the healing power of fibroblasts.”

SpinalCyte is the leader in the field of HDF therapy with 52 U.S. and international patents issued and 85+ patents pending focused on the clinical utility of fibroblasts.

“Fibroblasts are the regenerative cell source of the future,” said Pete O’Heeron, Chief Executive Officer of SpinalCyte. “The breadth of our intellectual property demonstrates the versatility of this technology and positions us as the unquestioned frontrunner in this emerging sector. We look forward to presenting new research from around the globe highlighting the promise of fibroblasts.”

Degenerative disc disease (DDD) is a condition in which a patient's spinal disc breaks down and can begin to collapse. It is estimated that 85% of people over the age of 50 have evidence of disc degeneration and over 1.3 million procedures a year are performed to treat the disease. The most common treatments for patients with DDD are either discectomy or spinal fusion. Discectomy is the partial or full removal of the degenerated disc to decompress and relieve the nervous system but can cause long term spinal pain. In a spinal fusion procedure, the entire disc is removed and the two adjacent vertebrae are fused together. It often increases strain on the adjacent discs and surrounding tissues leading to further degeneration.

CybroCell is the first off-the-shelf allogenic human dermal fibroblast (HDF) product for the treatment of degenerative disc disease. SpinalCyte's Phase 1/Phase 2 clinical trial for injected human dermal fibroblasts in the treatment of DDD demonstrated after 18 months, patients injected with CybroCell had sustained improvement in pain relief and increased back mobility.

Based in Houston, Texas, SpinalCyte, LLC, is a regenerative medicine company developing an innovative solution for spinal disc replacement using human dermal fibroblasts. Currently, SpinalCyte holds 52 U.S. and international issued patents and has filed for an additional 85+ patents pending and issued across a variety of clinical pathways, including disc degeneration, cancer, diabetes, liver failure and heart failure. SpinalCyte represents the next generation of medical advancement in cell therapy.